Overview
- Consolidated net profit rose 3.7% year on year to Rs 1,353.37 crore for Q2 FY26.
- Revenue from operations increased to Rs 7,589.44 crore, with EBITDA at Rs 1,895 crore and a 25% margin.
- The pharmaceuticals segment delivered Rs 7,291.43 crore in revenue, while new ventures contributed Rs 350.68 crore.
- Cipla launched six products in the quarter, marking a strategic entry into the Orthocare segment.
- The Board disclosed a succession plan with Achin Gupta slated to become MD & GCEO on April 1, 2026, subject to shareholder approval, as Umang Vohra steps aside and Meera Vanjari becomes Global General Counsel.